Catalio Capital Management — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+7 more
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Albert Seymour(Director)
BoardKush Parmar(Executive Officer, Director)Paula Soteropoulos(Director)Stephen Knight(Director)
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+7 more
Noetik builds AI models to identify cancer patients most likely to respond to treatments and to discover new oncology drug targets.
AI & Machine LearningBiotechHealthtechSouth San Francisco, US
Jacob Rinaldi(Executive Officer, Director, Promoter)inRonald Alfa(Executive Officer, Director, Promoter)Ron Alfa, MD, PhD(Founder)in
BoardJames Hardiman(Director)inAmy Schulman(Director)in
Co-investors11.2 CapitalBreakout VenturesLinearis VenturesNorth South VenturesDCVC (Data Collective)EPIC VENTURES+2 more
ProSomnus offers oral appliance devices for treating obstructive sleep apnea and snoring, positioned as an alternative to CPAP machines.
Digital HealthHealthtechMedical DevicesWellness & FitnessPleasanton, US
Leonard Liptak(Executive Officer, Director)Sung Kim(Executive Officer)Jason Orchard(Director)Steven Pacelli(Director)Heather Rider(Director)Laing Rikkers(Executive Officer, Director)
Co-investorsCatalio Capital Management, LPSpring Mountain Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.